Article Text

PDF

FRI0214 Incidence of pancreatic autoantibodies in primary sjÖgren syndrome
  1. K Aksu1,
  2. G Altan Oder1,
  3. Y Kabasakal1,
  4. G Keser1,
  5. V Inal1,
  6. A Isik1,
  7. S Cetinkalp2,
  8. E Doganavsargil1
  1. 1Rheumatology
  2. 2Endocrinology, Ege University, Faculty of Medicine, Izmir, Turkey

Abstract

Background Primary Sjögren (SjS) syndrome is one of the prototypes of autoimmune diseases.

Objectives We aimed to work out the incidence of pancreatic autoantibodies in this disease.

Methods Seventy-six patients (F/M: 71/5, mean age: 49 ± 13 years) diagnosed as primary SjS syndrome according to the San Diego criteria between February 1997 and December 2000, have been included in the study. Twenty two, age matched (52 ± 10 years) female patients with secondary SjS due to rheumatoid arthritis were defined as the control group. Healthy control group included 22 age matched (F/M: 21/1) patients. Immunosuppressive drug usage, liver or renal failure were within the exclusion criteria. Serum samples for anti-insulin (AIA), islet (ICA) and anti-insulin receptor (IRA) antibodies were obtained from all patients after an 18 h fasting.

Results The incidence of anti-insulin antibody was found as 17%, while it was 7% and%17 for islet antibodies and anti-receptor antibodies, respectively (Table 1). These values were not statistically significant when compared with secondary SjS and healthy control groups (p > 0.05).

Abstract FRI0214 Table 1

Incidence of pancreatic autoantibodies

Conclusion Incidence of pancreatic auto-antibodies in primary SjS with observed hyperactivity of B cells, was not found statistically different when compared with patient and healthy control groups.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.